Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

GENETIC TECHNOLOGIES LIMITED

INVESTOR PRESENTATION - GENETIC TECHNOLOGIES LIMITED

ASX:GTG

GENETIC TECHNOLOGIES LIMITED

Health Care

Genetic Technologies Limited (GTG) is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The Company's lead product is BREVAGenplus.

Market Cap

66.09m

Price at Close

$0.008

4w avg. Volume

4.65m

4w avg. Turnover

$38.99k

Announcements
announcementt+2 movementdate
  • US Securities & Exchange Commission FORM 20-F filing

    Periodic Reports

  • -

    22 Oct 2020

-

22 Oct 2020
  • Change in substantial holding

    Shareholder Details

  • 0.00%

    06 Oct 2020

0.00%

06 Oct 2020
  • Appendix 4G and Corporate Governance Statement

    Periodic Reports

  • -11.11%

    18 Sep 2020

-11.11%

18 Sep 2020
  • Annual Report to shareholders

    Periodic Reports

  • -11.11%

    18 Sep 2020

-11.11%

18 Sep 2020
  • Investor Presentation

    Periodic Reports

  • -10.00%

    16 Sep 2020

-10.00%

16 Sep 2020
  • US Sales commence via Online Health Platform

    Progress Report

  • +12.50%

    10 Sep 2020

+12.50%

10 Sep 2020
  • Nasdaq Compliance Confirmation

    Other

  • -20.00%

    01 Sep 2020

-20.00%

01 Sep 2020
  • Preliminary Final Report

    Periodic Reports · Market sensitive

  • -10.00%

    30 Aug 2020

-10.00%

30 Aug 2020
  • Change in substantial holding

    Shareholder Details

  • -9.09%

    25 Aug 2020

-9.09%

25 Aug 2020
  • Change in substantial holding

    Shareholder Details

  • +11.11%

    29 Jul 2020

+11.11%

29 Jul 2020
Market Data

Current Price

$0.008

52WK HIGH

$0.014

52WK LOW

$0.003

1YR RETURN

+60.00%

1YR RETURN VS. SECTOR

-323.81%

90 DAY RETURN

-20.00%

ASX RANK

959

/2,013

SECTOR RANK

5

/9

SHARES OUTSTANDING

8.26b
ASX:GTG

GENETIC TECHNOLOGIES LIMITED

Health Care

Genetic Technologies Limited (GTG) is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The Company's lead product is BREVAGenplus.

Market Cap

66.09m

Price at Close

$0.008

4w avg. Volume

4.65m

4w avg. Turnover

$38.99k

ASX:GTG is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.